This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMÁGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.








ACORDIS

Conflict Confliction
Confliction Confliction
Westeroof Sont Street,
Sections Son 440
Chiese Kingdom
Chiese Kingdom





Amiconique...

A A A A A PARISTON OF THE BEALTH OF THE BEAL


I vou ac en alle overheer. I Mourcean Tow Decine a Solf of the intermediate


- Revolutional vice Searce at the month of the tipe all vice of passed in espiration with the control of the cont
- (Constitution to edition with the second of the second of

Amicor Marketing Acordis UK Ltd Saint Street Bradford BD7 4AD England Visit the Amicor website to find out more about the full potential of this fibre, and to see what the experts say. Developed by Acordis to meet demands for increased www.amicor.co.uk freshness and comfort through textiles for home, activewear, hotels, leisure and healthcare markets. Amicor is a tradema

Stone of the stone

or Puro Fryour le Fryour le Seantlet Mittour III







is your beclas iresh and healthy as you think?

Statistic (Clivic line 70% of asthmatic the logness and setting the incition and line enterline of the property of the propert

To all years the condition may an intermediate the lay double distinction and the condition of the condition

Amiror almato improva ina dincia ciancino obaliargan evolutaro ambastida do Improva in milyindalida







Sniriey House, wilmslow Hoad: Didsbury: Manchester M20 2RE, UK

Institut of the International Association for Research and Testing in the Field of Textile Ecology

The company

ACORDIS ACRYLIC FIBRES WEST CROFT SAINT STREET GREAT HORTON BRADFORD BD7 4AD

is granted authorization according to Oeko-Tex Standard 100; in accordance with our Test Report No. 7821/STC003 to use the Oeko-Tex mark



for the following articles:

COURTELLE ACRYLIC FIBRE - produced by Acordis UK Ltd ACRYLIC FIBRE - AMICOR AB ACRYLIC FIBRE - AMICOR AF OUTLAST ACRYLIC FIBRE

The results of the inspection, made according to Oeko-Tex Standard 100 (Product Class I), have shown that the above mentioned goods meet the humano-ecological requirements of the current standard for yarns and fibres for adult and baby use.

The certified articles fulfil the requirements regarding the use of azo-dyestuffs of the German "Bedarfsgegenstandeverordnung", which came into force on April 1, 1996.

The holder of the certificate, who has made a conformity declaration according to EN 45014, is obliged to use the Oeko-Tex mark only in conjunction with products that conform with the sample initially tested.

The first certificate under this number was issued on 14th July 1995. The authorization granted today is valid until 14th September 2002.

Manchester, 26th September 2001

W. A

RC1(b)

Amicor Pure - Sci ntifically proves allergen reduction from th fibre's core

Acordis will reveal new research into allergy reduction and healthy bedding products at Heimtextil, Frankfurt. Successful trials and research carried out by John Maunder of Cambridge Entomology Department reveal a fresh direction in allergen prevention. This study measures Amicor Pure's effect against the growth of allergens across a variety of materials and uses the stringent standards set out by the World Health Organisation as a benchmark for these trials.

Results of allergen research

The standards that the World Health Organisation advocate come from recommendations by Thomas Platts-Mills and Alaine de Weck in a 1989 paper: Platts-Mills, TAE &* de Weck, AL (1989). Dust mite allergens & asthma: a worldwide problem, The Journal of Allergy and Clinical Immunology, 83:416-427. This measures the amount of allergen present and the potential health impact.

	W.H.O. RECOMMENDATIONS	AMICOR PURE RESULTS
Avoid primary sensitisation	10.0 μg / ml	0.4 μg / ml
Prevent allergic reaction / attack	2.0 μg / ml	0.4 μg / ml

Trials carried out by Cambridge Entomology Department - John Maunder, 2001

Amicor Pure keeps allergens to a consistent 0.4 μg / ml which is well within the recommended minimum for primary sensitisation and secondary allergic reaction.

The rise of allergies, in particular asthma sinusitis and allergic rhinitis, pose a real threat to future health. Specialist allergy doctors at the Red Cross Hospital, Barcelona agree that **the reduction** of allergens in our day to day environment is vital for two reasons:

- To avoid sensitisation in the first place and reduce the number of sufferers.
- To reduce allergens in our home environment so that they cannot trigger reactions or attacks.

"Amicor's key ingredient is an effective anti-fungal additive. Amicor Pure is the only anti-fungal fibre produced globally and is protected by patents. This latest research is a guarantee of effectiveness in allergen prevention and sets Amicor Pure apart from the competition," states Roland Cox Research and Development Manager for Amicor Pure.

-ends-

For further information please contact:

During Heimtextil

Roland Cox at:

Acordis UK Ltd +44 1274 571151 / roland.cox@acordis.com

Mobile: +44 (0)7767 756637

Caroline Powell at:

Acordis UK Ltd +44 1274 525322 / caroline.powell@acordis.com

Mobile: +44 (0)7770 744962

See the full story on Amicor at www.amicor.co.uk

Edit rs N tes:

Amicor Pure: Health Benefits Scientifically Proven

- 50 patients with a known history of allergy to house dust mite allergen took part in a trial completed over a 15 month period and recorded their symptoms and the medication required on a daily basis.
- 20% of patients supplied with Amicor Pure bedding had a reduction in all symptoms within the first few weeks.
- 81% of patients supplied with Amicor Pure bedding were able to use less medication during the trials.
- 96% of patients supplied with Amicor Pure bedding recorded a total improvement of symptoms.
- The results recorded were the same 12 months later, proving that Amicor Pure's effect remains constant.
- Placebo bedding (not containing Amicor Pure) was added to the second trial and those patients did not record any significant improvement.
- Amicor Pure's objective is to deliver comfortable, healthy textiles to improve every day lives.

Amicor Pure: Position statement

- Amicor Pure is the most secure way of delivering an effective anti-microbial in textiles.
- The scientific research behind Amicor Pure is thorough and takes into account public health and safety.
- Amicor Pure has Okotex certification.
- In human skin tests, Amicor Pure measured 'less of an irritant' than 100% cotton. This is considered harmless.
- All products are washable at 60 and 70 degrees.
- Amicor Pure is durable and designed to last for the lifetime of the product.

The Amicor Pure 'Sleep System' - Tried and tested.

Amicor Pure, providing a breath of fresh air for healthier bedding generally, as well as vital, proven protection for allergy sufferers.

The Amicor Pure 'Sleep System' can now provide proven and lasting protection from allergens by incorporating Amicor Pure fibre at the beginning of each product's life.

- Bed linen
- Quilts
- Pillows
- Mattress protectors
- Blankets
- Mattress filling
- Ticking
- Pyjamas and night wear

Amicor Pure fibre is in the second year of commercial development across Europe and the USA. Commercial products are now available for babies, children and adults of all ages. Please see the list of European Partners.

Amicor Pur Products – Heimt xtil 2002

Customer	Hall / Stand No.	Product
Bedeck (UK)	9.3 / E45	Bed Linen
Bodet & Horst (NL)		Blankets
Caleffi (I)	1.1 / D10	Quilts, pillows, mattress protectors
Centa Star (D)	8.0 F60	Quilts, pillows, mattress protectors
Coelima (P)	1.1 / C01	Bed Linen
Crespi (I)	9.1 / B86	Ticking, mattress protectors
Delux (S)	,	Quilts, pillows, mattress protectors
Demaflex (I)		Mattress protectors
Descamps (F)	1.2 / B18	Bed Linen
Diamond Spring (B)		Quilts, pillows, mattress protectors
Elytex (F)	•	Bed Linen
Emmebiesse / Allertec (I)	•	Bed Linen
Eurospuma (P)	1.1 / C01	Fibre filling, quilts, pillows, mattress protectors
Faratex (F)	8.0 / A60	Blankets
Fogarty (UK)	•	Quilts, pillows, mattress protectors
Flexilinea / Simmons (I)		Quilts, pillows, mattress protectors
Hagemann (D)	9.2 / D20	Blankets
Il Guanciale di Somma (I)	9.2 / D88	Quilts, pillows, mattress protectors
Joaquim Prata (P)		Blankets (Baby)
Lamierinho (P)	1.1 / G02	Bed Linen
Lava (P)		Ticking
Lestra (F)		Quilts
Marmara(T)	4.0 / G70	Bed Linen
Mattes & Ammann (D)		Mattress protectors
Metzeler Schaum GmbH (D)	9.1 / E53	Mattress protectors
Mitsa (E)		Mattress protectors
Morup Stof (B)		Ticking
Motte – Poyet (F)	9.2 / F11	Mattress protectors, blankets
Nueva Hildesa (E)		Blankets (Baby)
Outerinho (P)		Bed Linen
Para SpA (I)?	4.2 / F60	Upholstery Fabric
Piel (E)		Blankets, bed linen
Rasilan (E)	9.1 / E35	Blankets
Textil Munoz S.L. (E)	8.0 / K62-66	Blankets (Baby)
Textiles Maes (P)	9.0 / A61?	Ticking
Textils Mora S.A.L. (E)	9.2 / D11	Blankets
Toison D'Or S.A. (F)	9.2 / F11	Blankets
Trendsetter (UK)	9.1 / E85	Quilts, pillows, mattress protectors
Valrupt (F)		Bed Linen
Velamen S.A. (E)	8.0 / A11	Quilts, pillows, mattress protectors
Wellness (D)	8.0 / F08	Bed Linen
Zorlu / Kortecks (T)	3.0 / E11	Bed Linen



RESULTS OF 2^{ND} OBSERVATIONAL STUDY CONDUCTED ON PATIENTS ALLERGIC TO DOMESTIC MITES AFTER THE USE OF AMICOR FIBRE AND A CONTROL GROUP

Dr. M. de Molina Dr. E. Pinto

Hospitalet de Llobregat, 20/6/2001





OBJECTIVES

The objective of the study was to evaluate the clinical situation of patients who suffer from extrinsic rhinitis and / or bronchial asthma and are sensitive to mites in domestic dust after the second consecutive year of use of materials (blankets, eiderdowns, mattress covers and pillowcases) made from Amicor fibre and compare them with a study group that shows the same pathology.

MATERIAL AND METHODS

The 48 patients included in the original study in 1999 were invited to take part in the second phase of the study in order to evaluate their symptoms during the course of a further 13 weeks. The second study period began at the end of November 2000.

Twenty patients with the same clinical characteristics were selected as a control group.

RATE OF COMPLETION

Of the 48 patients included in the second phase, 47 completed the study. Of the 20 in the control group, 18 completed the programme.



RESULTS

After analysing the information on the data sheets of each patient (Supplement 1 and Supplement 2), we could see that 45 of the 47 patients provided with Amicor products showed a effective improvement (96%), while 40 patients experienced a total improvement (85%).

Table of results of Patients Equipped with Amicor Pure products.

1(0)1'A		- PXV	rio) et	otear		ichine(C	THYE		PARTOR	
PAYMEN	118	2011				PROX	IMMIDINI	DAY!	RONTA	11/18/17
			11		9					
,			A			3			3	derder sch
			RVA						3(0)	
470				ie sie sie s		48/10	SOUR		(0) i5) elitéroi	915
1						Or.	V.		W. W.	

The results for the 18 patients not equipped with Amicor products indicated an effective improvement in 67% (12/18) of cases and a total improvement in 44% (8/18).

Table of results for Patients NOT Equipped with Amicor Pure products.

TOTAL	PATER OF OCA	EDECCTIAVI	i i i	DIVAL
PATHENIS		IMPROVEME	NE EMPRO	NIEMIENII.
8 10 10 10 10 10 10 10 10 10 10 10 10 10	R R	165 E		(5)
0.7	/A	100 100 100 100 100 100 100 100 100 100		3
	RVA C			
0		diz persons	8 i	G15(0)1K
70		67%	Ž	49/68 35 S




A significant difference emerges regarding the group of patients who not only followed the doctors' instructions but were also equipped with Amicor Pure products. This difference amounts to 29% in the case of Effective Improvement, reflecting an increase of 43%, and a difference of 41% in the case of Total Improvement, reflecting an increase of 93%. This difference can be attributed to the effectiveness of Amicor products.

Comparison of results between patients who were equipped and NOT equipped

	TOTAL PATIENTS		CTIVE VEMENT	TO? IMPROV	TAL EMENT
legindinjerekî	4. Z J/	45 jagers	9.67%	4(0) p.o.\$.	\$5 Va
- NOT Equipped /->	118	412 pers*	67.96	8-pers	44%
Difference in			29		41
percentage points					
Increase			43%		93%
Equip./NOT Equip.					

Chart to compare Patients who were equipped with those NOT equipped





CONCLUSIONS

> The clinical improvement observed in the patients in the control group can be attributed to the observation of therapeutic measures prescribed by the team of doctors.

> In view of the results, we can conclude that there are extremely significant differences between the two groups of patients:

* Effective improvement: Patients equipped with Amicor: 96%

Patients not equipped: 67%

* Total improvement: Patients equipped with Amicor: 85%

Patients not equipped: 44%

> The differences that exist between the groups can be attributed to the effectiveness of Amicor products.

- > Bearing in mind the results obtained, it is worthwhile stressing that there are no significant differences between the groups of patients equipped with Amicor fibre products in the different years of 1999 and 2000.
- Another aspect worth highlighting is the reduction in the consumption of medicines / drugs in the "equipped" group (75%) compared with the equivalent percentage of 55% for the "unequipped" group.



AUTHORS / RESEARCHERS

Dr. Montserrat de Molina Gorina

Head of the Allergy Unit at the Consorci Sanitari Creu Roja a Catalunya ("Red Cross Health Consortium in Catalonia") - L'Hospitalet de Llobregat ("Llobregat Hospital"). Specialist in Paediatrics and Child-care following study at the Faculty of Medicine at the University of Barcelona.

Specialist in the Study of Allergies following study at the same University.

Dr. Ester Pinto Nogués

Assistant Doctor at the Allergy Unit at the Consorci Sanitari Creu Roja a Catalunya - L'Hospitalet de Llobregat.

Specialist in the Study of Allergies following study at the Autonomous University of Barcelona.

Hospitalet de Llobregat, June 20th, 2001

[Signatures of the Researchers]

Firmas de las investigadoras





Red Cross Endorsement of Amicor Pure Trials

'We' have carried out trials through the Red Cross Hospital, Barcelona, using Amicor Pure bedding materials and a placebo, to research the benefits to patients who are sensitive to the allergen DER P1.

The patients all have a clinical history with our department and suffer from asthma, allergic rhinitis and sinusitis.

Following scientific research that measured the reduction of DER P1 in bedding containing Amicor Pure, we were interested to see the human effect that this reduction would reveal, in a clinical environment.

The results show that there is a noticeable improvement in the symptoms of patients using Amicor Pure bedding compared to those provided with placebo bedding.

We also measured the effect of Amicor Pure bedding after a twelve month period, resulting in consistent performance between both periods. This proves that Amicor Pure's effectiveness in keeping allergens to a minimum does not diminish over this time period.

Our patients also noticed that the bedding was comfortable and soft, unusual for bedding materials, which reduce allergens so effectively.

The results that we reported mean that we are happy to recommend Amicor Pure bedding as a method of reducing the allergen DER P1 and keeping it at the lowest levels possible in allergy sufferers beds. We believe that the prevention of allergen, wherever possible, will aid individual sufferers to live a healthier life.

DRA. DE MOLINA DRA. PINTO

L'Hospitalet de Llobregat 24 de Octubre 2001

EXHIBIT



Amicor*

Press Release: Expofil, Paris - June 4th 2002

Amicor Pure achieves the British Allergy Foundation's 'Seal of Approval'

Amicor Pure, produced by Acordis, is the first fibre to be awarded the Seal of Approval by the British Allergy Foundation. Amicor Pure will be presented at Expofil as the latest technology in smart fibre's endorsed for consumer health and well being to promote it's feel

good factor to the European spinning industry.

The British Allergy Foundation are satisfied that the scientific research carried out on their behalf reveals that 'Amicor Pure fibre has a notable effect on reducing the number of mites present in bedding material (feeding on human skin scales) and as a consequence, has a notable effect on the amounts of the allergen Der P1 present. The use of Amicor Pure, therefore, is considered to be of long-term benefit to the increasing number of dust mite allergy sufferers'. Dust mite populations are thriving in our modern homes. The increasing use of central heating, sealed windows and en-suite bathrooms creates the ideal environment for dust mites to colonise our homes. Today's home provides the vital warmth and humidity levels needed for the fungus, aspergillus repens, to turn our dead skin scales into the nutritious form that is needed by the mites. Amicor Pure inhibits the growth of this fungus within the material, removing the food source of the dust mite. Amicor Pure dramatically reduces the mite's breeding rate and they simply cannot colonise in new Amicor Pure bedding articles.

The benefits of this are two-fold. Amicor Pure will help to prevent the likelihood of sensitisation via bedding materials, in the first place. Babies and children are the most susceptible to allergens, with 1 in 5 children given as the average in the UK at present. Secondly, for those people with an existing allergy to Der P1, Amicor Pure provides a much healthier sleeping environment with dramatically reduced dust mite colonies.

-ends-

For further information please contact:

Car line Powell at Acordis / Amicor Marketing Department +44 1274 525322

Sarah Crawford at Acordis / Amicor Research and development +44 1274 525323

(mobile +44 7770 477962)

(mobile +44 7831 250750)



Editors' N tes

Doctors and allergy specialists agree that the prevention of allergens is an important factor in helping to reduce the long-term incidence of asthma, allergic rhinitis and sinusitis, all triggered by Der P1. The World Health Organisation guidelines measure the potential harm of Der P1 at two levels. (Please see release of 9th January 2002 for further information.)

How is Amicor different and how is it used?

"Most bedding suitable for allergy sufferers uses a barrier method where the outer fabric is impermeable to mites. Because Amicor Pure is a fibre, it is soft, versatile and can be blended invisibly throughout a broad range of materials already used in our homes. Once Amicor Pure has been blended into each fabric it provides a zone of protection for the whole product that will last for the lifetime of that product. The softness and accessible consumer pricing are designed to keep Amicor Pure as consumer-friendly as possible". Caroline Powell, Amicor Marketing.

Amicon*pure

Amicor Pure is already being used commercially to protect bedding materials from mattress fillings and cover fabrics to pillows, quilts and mattress protectors. Commercial Products include:

- Mothercare pillow, quilt, mattress cover, blanket
- Next pillow, quilt, mattress protector
- Fogarty (brand) pillow, quilt, mattress protector
- Bedeck (brand) bed linen (sheets and pillow cases, including children's range.)
- Mora (brand) blankets

As phase two of this project Amicor Marketing are already working with the British Allergy Foundation and their customers to clearly identify these products in store and to raise awareness with allergy sufferers across the UK. Amicor Pure is not a clinical product designed to *cure* allergy sufferers. It is a complementary product that can benefit the lives of existing sufferers and could help prevent sensitisation for the next generation.

Acordi is a multinational group of businesses, supplying customers throughout the world with man-made fibres and speciality materials for industrial, textile, medical, and hygiene applications.

www.amicor.co.uk (existing site) / www.amicor-health.com (development site)



SEAL OF APPROVAL

CERTIFICATE

This is to certify that

ACORDIS LTD

have been awarded the British Allergy Foundation Seal of Approval for their product

AMICOR PURE ANTI-BACTERIAL/ ANTI-FUNGAL MATERIAL

Signed: Muriel Simmons, Chief Executive

Date: 19th April 2002





Leaflet and Labelling Order Form

Home Textiles



Customer Reference

Company name*	Amicor Certification number [*]
Contact name*	Phone number*
	Fax number
	Email address

Amicor Pure Leaflets - First Issue / Red Cross

LEAFLET TYPE	LANGUAGE	CODE	QUANTITY
'Sleep peacefully'	English	APL/1/E	
'Sonni tranquilli'	Italien	APL/1/I	
'Dorme tranquillement'	French	APL/1/F	
'Duerma plácidamente'	Spanish	APL/1/S	
'Durma Serenamente'	Portuguese	APL/1/P	
'Schlafen Sie unbesorgt!'	German	APL/1/G	

Amicor Marketing can supply customised leaflets on orders over 15,000. Please contact Caroline Powell for direct branding support.

Sew-in label

LABEL TYPE	PRESENTATION	CODE	QUANTITY
Amicor Pure	Rolls of 1,000	APSL/1/M	

Amicor Marketing cannot supply customised sew-in labels.

Delivery Instructions

Address to send goods*	Signature / Company Stamp*
	F EXH BUT
·	
	Date Ordered*

Ordering

Please fill in all areas marked '*'. We cannot arrange delivery without these details.

Please send your order to:

Amicor Marketing Acordis UK Ltd Saint Street Bradford BD7 4AD

Tel: +44 1274 571151

r_... . 44 4074 EOE3EO/ . 44 4074 EOE3SE

Email: marilyn.goodings@acordis.com Copies: caroline.powell@acordis.com

PLEASE ALLOW 7 DAYS FOR DELIVERY IN EUROPE